CCC
KTTA icon

Cable Car Capital’s Pasithea Therapeutics KTTA Stock Holding History

Cable Car Capital’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.55M Buy
3,000,000
+1,793,621
+149% +$1.23M 0.03% 89
2026
Q1 		$895K Buy
1,206,379
+706,379
+141% +$591K 0.31% 65
2025
Q4 		$645K Buy
+500,000
New +$439K 0.02% 65

Other funds holding KTTA

SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Cable Car Capital's KTTA Position: Q2 2026 in Review

Cable Car Capital increased its Pasithea Therapeutics (KTTA) stake by 149% in Q2 2026, buying an estimated $1.23M and bringing the position to 3,000,000 shares worth $1.55M. The position accounts for 0.03% of the portfolio, ranked #89.

Cable Car Capital first reported a position in KTTA in Q4 2025 and has held it in 3 quarters since. 25 funds tracked by Wall St. Rank hold KTTA as of Q2 2026.

  • Cable Car Capital held 3,000,000 shares of Pasithea Therapeutics worth $1.55M as of Q2 2026.
  • Cable Car Capital bought 1,793,621 Pasithea Therapeutics shares in Q2 2026, an estimated $1.23M.
  • Pasithea Therapeutics made up 0.03% of Cable Car Capital's portfolio in Q2 2026, its #89 holding.
  • Cable Car Capital first reported a position in Pasithea Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 25 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q2 2026.

Based on Cable Car Capital's 13F filing for Q2 2026, filed 14 Aug 2026.